RIGEL PHARMACEUTICALS INC (RIGL)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, RIGEL PHARMACEUTICALS INC reported revenue of $294.28M, up 64.1% from the prior year. The company was profitable, with a net margin of 124.7%. It held $513.59M in total assets against $122.11M in total liabilities.
Key ratios (FY2025)
42.6%
Operating margin
124.7%
Net margin
93.8%
Return on equity
+64.1%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $294.28M | $179.28M | $116.88M | $120.24M | $149.24M | $108.62M | $59.29M | $44.51M | $4.48M | $20.38M |
| Cost of Revenue | $19.62M | $18.65M | $7.11M | $1.75M | $1.08M | $895.0K | $906.0K | $287.0K | — | — |
| Operating Income | $125.47M | $24.19M | -$20.49M | -$55.55M | -$12.50M | -$28.97M | -$69.09M | -$72.68M | -$79.62M | -$69.74M |
| Net Income | $367.02M | $17.48M | -$25.09M | -$58.57M | -$17.91M | -$29.74M | -$66.89M | -$70.48M | -$77.99M | -$69.22M |
| EPS (Diluted) | $19.48 | $0.99 | $-1.44 | $-3.44 | $-0.11 | $-0.18 | $-0.40 | — | — | — |
| Total Assets | $513.59M | $163.98M | $117.22M | $134.28M | $167.33M | $110.38M | $147.57M | $139.11M | $119.11M | $78.13M |
| Total Liabilities | $122.11M | $160.69M | $145.87M | $147.90M | $136.95M | — | — | — | — | — |
| Shareholders' Equity | $391.48M | $3.29M | -$28.64M | -$13.62M | $30.37M | $34.03M | $53.81M | $109.88M | $100.65M | $55.03M |
| Cash & Equivalents | $40.58M | $56.75M | $32.79M | $24.46M | $18.89M | $30.37M | $22.52M | $76.32M | $38.29M | $17.63M |
| Operating Cash Flow | $75.66M | $31.47M | -$5.74M | -$73.76M | $5.88M | -$52.19M | -$41.51M | -$58.83M | -$77.56M | -$75.89M |
| Capital Expenditures | — | — | — | $450.0K | $627.0K | $1.26M | $1.46M | $1.11M | $164.0K | $804.0K |
| Shares Outstanding | 18.31M | 17.71M | 17.48M | 173.40M | 171.60M | 169.32M | 167.99M | 167.17M | 146.81M | 99.27M |